Nasdaq

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Nasdaq

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
BioWorld

Alterity develops novel MRI biomarker to track disease progression in MSA

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...
Monthly Prescribing Reference

Iron Chaperone Granted Fast Track Status for Multiple System Atrophy

Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
The American Journal of Managed Care

MRI Study Reveals Hypothalamic Atrophy Across Multiple Subregions in Narcolepsy Type 1

High-resolution 3T T1 MRI with FreeSurfer v7 segmentation identified smaller whole hypothalamic volume in narcolepsy type 1 after adjustment for age, sex, and intracranial volume. Subregional analysis ...